AEterna Zentaris PE Ratio 2006-2021 | AEZS

Current and historical p/e ratio for AEterna Zentaris (AEZS) from 2006 to 2021. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. AEterna Zentaris PE ratio as of October 15, 2021 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

AEterna Zentaris PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2021-10-15 0.60 0.00
2021-06-30 0.88 $-0.08 0.00
2021-03-31 1.14 $-0.21 0.00
2020-12-31 0.43 $-0.15 0.00
2020-09-30 0.35 $-0.18 0.00
2020-06-30 0.80 $-0.18 0.00
2020-03-31 0.51 $-0.02 0.00
2019-12-31 0.91 $-0.36 0.00
2019-09-30 1.03 $-0.62 0.00
2019-06-30 2.95 $-0.75 0.00
2019-03-31 4.65 $-0.92 0.00
2018-12-31 2.94 $0.25 11.76
2018-09-30 1.74 $0.53 3.28
2018-06-30 1.95 $0.07 27.86
2018-03-31 1.46 $0.05 29.20
2017-12-31 2.36 $-1.13 0.00
2017-09-30 2.03 $-1.81 0.00
2017-06-30 1.00 $-1.81 0.00
2017-03-31 3.00 $-2.34 0.00
2016-12-31 3.60 $-2.40 0.00
2016-09-30 3.44 $-3.15 0.00
2016-06-30 3.26 $-9.54 0.00
2016-03-31 3.32 $-22.83 0.00
2015-12-31 4.48 $-35.46 0.00
2015-09-30 8.80 $-28.00 0.00
2015-06-30 28.10 $-41.00 0.00
2015-03-31 53.62 $-36.00 0.00
2014-12-31 60.00 $-31.00 0.00
2014-09-30 134.00 $-59.00 0.00
2014-06-30 116.10 $-26.00 0.00
2014-03-31 117.00 $20.00 5.85
2013-12-31 138.00 $35.00 3.94
2013-09-30 151.00 $28.00 5.39
2013-06-30 186.00 $-20.00 0.00
2013-03-31 188.00 $-33.01 0.00
2012-12-31 238.00 $-105.99 0.00
2012-09-30 420.00 $-118.98 0.00
2012-06-30 303.00 $-77.99 0.00
2012-03-31 1284.00 $-173.97 0.00
2011-12-31 924.00 $-179.97 0.00
2011-09-30 912.00 $-155.97 0.00
2011-06-30 1320.00 $-233.95 0.00
2011-03-31 1164.00 $-197.96 0.00
2010-12-31 1032.00 $-179.96 0.00
2010-09-30 780.00 $-47.99 0.00
2010-06-30 690.00 $-89.98 0.00
2010-03-31 474.00 $-197.96 0.00
2009-12-31 484.14 $-281.94 0.00
2009-09-30 732.00 $-557.89 0.00
2009-06-30 1038.00 $-599.88 0.00
2009-03-31 528.00 $-689.86 0.00
2008-12-31 294.00 $-671.87 0.00
2008-09-30 354.00 $-665.87 0.00
2008-06-30 630.00 $-605.88 0.00
2008-03-31 618.00 $-425.92 0.00
2007-12-31 924.00 $-365.93 0.00
2007-09-30 1572.00 $233.95 6.72
2007-06-30 2076.00 $257.95 8.05
2007-03-31 2274.00 $293.94 7.74
2006-12-31 2430.00 $323.94 7.50
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.073B $0.004B
AEterna Zentaris Inc. is a biopharmaceutical company focused on endocrine therapy and oncology. Its lead endocrinology program is a Phase 3 trial in benign prostatic hyperplasia (BPH) with cetrorelix, an LHRH antagonist already marketed for in vitro fertilization under the brand name Cetrotide. The lead oncology program is a Phase 2 trial in endometrial and ovarian cancer with AEZS-108, a targeted cytotoxic peptide conjugate. Other lead compounds include ozarelix for BPH and prostate cancer as well as perifosine for multiple cancers.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.683B 8.63
Bio-Rad Laboratories (BIO.B) United States $21.975B 46.83
QIAGEN (QGEN) Netherlands $11.773B 19.94
Biohaven Pharmaceutical Holding (BHVN) United States $8.738B 0.00
Emergent Biosolutions (EBS) United States $2.722B 6.57
Arcus Biosciences (RCUS) United States $2.455B 0.00
Myovant Sciences (MYOV) United Kingdom $1.915B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.755B 0.00
Zymeworks (ZYME) Canada $1.208B 0.00
Ambrx Biopharma (AMAM) United States $0.470B 0.00
SQZ Biotechnologies (SQZ) United States $0.342B 0.00
Enzo Biochem (ENZ) United States $0.183B 18.00